Panaxia Global, the controlling owner of Panaxia Labs Israel Ltd. Israel’s largest manufacturer of medical cannabis products, and its partner, Neuraxpharm, Europe’s leading pharmaceutical company specialized in the central nervous system (CNS) today announced they are expanding their strategic collaboration into the French market. They have signed a binding memorandum of understanding between Panaxia and subsidiary Neuraxpharm France for the manufacture, commercialization, and distribution of Panaxia’s advanced medical cannabis products in France. The commercial collaboration between the parties is based on a model much like that in Germany: Panaxia will be responsible for manufacturing the products it has developed at strict clinically-backed standards, and Neuraxpharm will be responsible for marketing, branding, distribution, and sale of the products to physicians, patients, and pharmacies in France.

Sean Hocking, Cannabis Law Report, 11/23/2020 22:35:23

Open article: